You are here: Industry Insights > Almirall

News List

Almirall signs option agreement to acquire Bioniz Therapeutics pharmaceutical-technology
January 13, 2020
Spanish drugmaker Almirall has signed an option agreement to acquire Bioniz Therapeutics, a clinical-stage biopharmaceutical company in California.
WuXi Biologics and Almirall Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases En-CPhI.CN
January 09, 2020
WuXi Biologics announced the signing of a strategic collaboration agreement enabling Almirall to leverage the proprietary WuXiBody™ platform to develop bispecific antibodies for dermatological diseases.
Almirall signs deal for Iktos’ AI technology in drug design pharmaceutical-technology
December 16, 2019
Spanish pharmaceutical firm Almirall has agreed with Iktos to leverage the latter’s generative modelling artificial intelligence (AI) technology to design novel drugs.
Almirall secures EIB grant to support research activities pharmaceutical-technology
June 28, 2019
The European Investment Bank (EIB) has granted a €120m loan to Spanish pharmaceutical company Almirall to support its research, development and innovation (RDI) activities related to skin healthcare therapeutic products.
HitGen and Almirall Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration pharmafocusasia
March 27, 2019
HitGen Ltd announced that the company has entered into a research collaboration with Almirall to identify novel small molecule leads for targets of interest. In this collaboration, HitGen will apply its advanced technology platform, based on DNA-encoded l
HitGen, Almirall to identify novel drug targets biospectrumasia
March 26, 2019
HitGen will receive upfront payments, and be eligible for milestone payments from Almirall
Almirall and X-Chem Announce Dermatology-Focused Drug Discovery Collaboration pharmafocusasia
December 13, 2018
X-Chem, Inc., a privately held biotechnology company applying its innovative drug discovery platform to the generation of novel small molecule therapeutics....
Almirall's Ilumetri scores EU approval in chronic plaque psoriasis pharmafile
September 20, 2018
Hot on the heels of the European Academy of Dermatology and Venereology Congress (EADV) 2018 where psoriasis took centre stage...
Almirall steps into psoriasis market with Ilumetri approval pharmatimes
September 20, 2018
The European Commission has approved Almirall’s Ilumetri for moderate-to-severe chronic plaque psoriasis.
Almirall steps into psoriasis market with Ilumetri approval pharmatimes
September 20, 2018
The European Commission has approved Almirall’s Ilumetri for moderate-to-severe chronic plaque psoriasis.

Previous page 1 2 Next page